Thermo Fisher Scientific Announces 4th Annual Cellome Award Winner
News Feb 26, 2014
Thermo Fisher Scientific, this week will present its 2014 Cellome Award to the authors of the peer-reviewed article, “A regenerative approach to the treatment of multiple sclerosis,” that was featured in the October 2013 issue of Nature.
Vishal Deshmukh, of The Scripps Research Institute will be accepting the award on behalf of all the contributing authors of the paper during the Cambridge Healthtech Institute’s High Content Analysis Meeting, February 19-20, 2014 in La Jolla, CA.
Contributing to the paper’s selection was the use of high content technology and its potential clinical impact by showing the effectiveness of benztropine administration alone or in conjunctive therapy in a Multiple Sclerosis model to enhance remyelination and functional recovery.
The Thermo Scientific Cellome Award is presented annually by Thermo Fisher Scientific’s cellular imaging and analysis business to the authors of the most impactful peer-reviewed article which showcases high content technology as a fundamental method.
Papers using Thermo Scientific cellular imaging and analysis products are collected and reviewed throughout the year, and one paper is selected which represents the best use of high content technology in life science research.
“We congratulate Vishal and his team on receiving this year’s award,” said Audra Ziegenfuss, technical product manager, cellular imaging and analysis, Thermo Fisher. “This in vivo evidence contributes to the development of novel therapies in the treatment of multiple sclerosis and ultimately improved clinical management of this patient population.”
“I have taken a phenotypic rather than target based approach using various readouts, including high-throughput high content imaging,” said Deshmukh. “I am extremely happy to receive this award as recognition of our HCI-HTS efforts and hope to continue using this approach in various other assays."
Contributors to the Nature paper include: Vishal A. Deshmukh, Virginie Tardif, Costas A. Lyssiotis, Chelsea C. Green, Bilal Kerman, Hyung Joon Kim, Krishnan Padmanabhan, Jonathan G. Swoboda, Insha Ahmad, Toru Kondo, Fred H. Gage, Argyrios N. Theofilopoulos, Brian R. Lawson, Peter G. Schultz, and Luke L. Lairson.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018